Posttreatment Gallium-68 FAP-2286 Positron Emission Tomography/Computed Tomography Parameters for Response and Survival Assessment After Lutetium-177 FAP-2286 Radioligand Therapy in Advanced Solid Tumours (EANM 2026) - Sep 29, 2026 - Abstract #EP-1000; "In patients with advanced solid tumours treated with two cycles of lutetium-177 FAP-2286, posttreatment changes in maximum standardised uptake value on gallium-68 FAP-2286 positron emission tomography/computed tomography were associated with treatment response and survival, supporting its potential utility as an imaging biomarker for early response assessment and prognostic stratification."
Metastases • Oncology • Solid Tumor
|